stockdaleiqemico1521.blogspot.com
Hobbs’ new job is president and CEO of (Nasdaq: which announced the news on Monday. The company did not say what 51, will earn. Hobbs replacesx Richard Taney, who will remain with the company on its boardcof directors. Hobbs has been a board member sincdeOctober 2008. Delcath’s medical devices focus on cancee treatments. The New York City-based company is testinb a new system for deliverinbg drugs to treat liver Company leaders said a growing push to commercializwe their products led them tohire Hobbs. “Eamonhn is a proven leader with extensive experiencew in all aspects of medicaldevice commercialization,” said Dr.
Harolsd Koplewicz, chairman of Delcath’s board. Delcath has accumulated $45.8 million of net losses sincw it openedin 1988. Last fiscal the company posted a net lossof $6.9 million, or 27 centa per diluted share. "We have had no revenuwe to date, a substantial accumulated deficit, recurrint operating losses and negativecash flow,” the company said in its latest annuaol report, issued earlier this year. Hobbs is the co-founder and forme r CEO of (Nasdaq: ANGO), a medical devicre company in Queensbury. AngioDynamics focuses on oncology, radiology and vascular AngioDynamicshad record-high revenure of $166.5 million in its latest fiscal year, whicu ended in May.
Hobbsa stepped down from his role as presidenyt and CEO at AngioDynamicsin March, and he was replacerd by Jan Keltjens. Hobbs remained vice chairmaj untilMay 8, when he resigned that position and left the At the time, AngioDynamics said his resignation was not prompted by any disagreementw with the company.
Aucun commentaire:
Enregistrer un commentaire